Non-small-cell lung carcinoma

Jounce Therapeutics Reports Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, August 5, 2021
Public expenditure, Insurance, Icos, Cancer, LILRB2, Non-small-cell lung carcinoma, Poster, Safety, Gilead Sciences, Asco, LILRB4, Annual report, Intellectual property, Food and Drug Administration, ID, Immunotherapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Therapy, Marketing, Security (finance), Investor, Completeness, Io, Tumor microenvironment, Immune system, Macrophage, CCR8 (gene), Toxicity, Food, Nasdaq, GLOBE, Conference, U.S. Securities and Exchange Commission, Investment, Webcast, American Society of Clinical Oncology, Private Securities Litigation Reform Act, Programmed cell death protein 1, Annual general meeting, Program, LILRB1, Patient, COVID-19, Society, Pharmaceutical industry

CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Key Points: 
  • - INNATE monotherapy dose escalation enrollment completed and target dose selected, on track to initiate indication specific expansions in third quarter 2021-
    - Ended the quarter with $246.1 million in cash, cash equivalents and investments -
    CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the second quarter ended June30, 2021 and provided a corporate update.
  • Second Quarter 2021 Financial Results:
    Cash position: As of June30, 2021, cash, cash equivalents and investments were $246.1 million, compared to $213.2 million as of December31, 2020.
  • License and collaboration revenue: Jounce recognized $25.4 million of license and collaboration revenue during the second quarter of 2021.
  • The decrease in net loss and net loss per share was attributable to revenue recognized in the second quarter of 2021.

Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer

Retrieved on: 
Thursday, August 5, 2021
Company, Nature, Forest Law Enforcement and Governance Program, Research, Judgement, U.S. Securities and Exchange Commission, Casirivimab/imdevimab, Product, Privacy, Patent, Government, Intellectual property, Large-cell lung carcinoma, Lymphatic system, Private Securities Litigation Reform Act, Form 20-F, Patient, COVID-19, Twitter, Annual report, Severe acute respiratory syndrome coronavirus 2, EMA, Dupilumab, Non-small-cell lung carcinoma, SEC, Food and Drug Administration, Social media, Medicare, Alirocumab, Health, AMF, Pharmacy, Forward-looking statement, Pharmaceutical industry

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.

Key Points: 
  • This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
  • Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions.
  • Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
  • Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website ( http://newsroom.regeneron.com ) and its Twitter feed ( http://twitter.com/regeneron ).

Arcus Biosciences to Participate at the 2021 Wedbush PacGrow Virtual Healthcare Conference

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Pharmaceutical, Health, Nursing, Cancer, List of life sciences, NT5E, Webcast, Lymphatic system, Non-small-cell lung carcinoma, New York Stock Exchange, Prostate, AstraZeneca, Gemcitabine, Conference, Arcus, Disease, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 1:45 p.m. Eastern Time.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 1:45 p.m. Eastern Time.
  • A live audio webcast of the presentation will be available by visiting the Investors section of the Arcus website at www.arcusbio.com .
  • A replay of the webcast will be available for at least two weeks following the live event.
  • Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs.

eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer

Retrieved on: 
Wednesday, August 4, 2021
Biomarkers, Biology, Branches of biology, Clinical medicine, KRAS, Non-small-cell lung carcinoma

eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer (NSCLC).

Key Points: 
  • eFFECTOR expects to initiate multiple indication-specific expansion cohorts in ER+ breast cancer and KRAS-mutant non-small cell lung cancer (NSCLC).
  • The Phase 2a expansion cohorts will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of zotatifin in subjects with biomarker-positive solid tumor malignancies, including ER+ breast cancer and KRAS-mutant NSCLC.
  • eFFECTOR expects to present additional data from the Phase 1 dose escalation portion of the trial, as well as preliminary response data from Phase 2a expansion cohorts, at a medical conference in 2022.
  • Zotatifin, eFFECTORs inhibitor of eIF4A, is currently being evaluated in a Phase 2a clinical trial in patients with breast cancer and KRAS-mutant NSCLC.

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference

Retrieved on: 
Wednesday, August 4, 2021
Pharmaceutical companies, Health care, Companies, Regulus Therapeutics, PTC Therapeutics

NEW YORK and SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 10:20 a.m.

Key Points: 
  • NEW YORK and SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a panel discussion at the Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 11, 2021 at 10:20 a.m.
  • Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
  • Zentalis has licensed ZN-c3, ZN-c5 and ZN-d5 to its majority-owned joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Mersana Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

Retrieved on: 
Wednesday, August 4, 2021
Lung cancer, Non-small-cell lung carcinoma

A live webcast of the panel will be available on the Investors & Media section of Mersanas website at www.mersana.com .

Key Points: 
  • A live webcast of the panel will be available on the Investors & Media section of Mersanas website at www.mersana.com .
  • Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer.
  • UpRi is also being evaluated in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with NSCLC adenocarcinoma.
  • The Companys early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Companys Immunosynthen platform.

Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021

Retrieved on: 
Wednesday, August 4, 2021
Cancer, Branches of biology, Causes of death, GBM, Glioblastoma, Glioblast, Breast cancer

Mr. Zarrabian will deliver his corporate presentation on Monday, August 9, 2021 at 2:00 p.m.

Key Points: 
  • Mr. Zarrabian will deliver his corporate presentation on Monday, August 9, 2021 at 2:00 p.m.
  • The live webcast will be available on the BTIG conference website at the time of the event, after which it will be available through BTIG research access.
  • Investors can also request a one-on-one meeting with Mr. Zarrabian to be arranged following the conclusion of the conference.Please contact a BTIG conference representative.
  • Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).

Rybrevant Amivantamab FDA Approval To Drive Bispecific Antibody Sales To US 20 Billion by 2026

Retrieved on: 
Tuesday, August 3, 2021
Medical specialties, Clinical medicine, Immunology, Medicine, Monoclonal antibody, Antibody, Bispecific monoclonal antibody, Epidermal growth factor receptor, MorphoSys, Monoclonal antibody therapy

https://www.kuickresearch.com/report-global-usa-europe-japan-bispecific-...

Key Points: 
  • Recently, the progress in antibody and recombinant DNA technology, various platforms for generating bispecific antibodies has been developed.
  • In May, 2021 US FDA has granted approval to Rybrevant (Amivantamab) which is a novel bispecific antibody developed by Janssen Pharmaceuticals.
  • Rybrevant is a fully human bispecific antibody which is directed against EGFR and MET receptors.
  • Among region, US is currently dominating the global bispecific antibody market and is expected to lead the market during the forecast period.

Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical and Mechanism of Action Data for RBN-2397

Retrieved on: 
Thursday, July 22, 2021
Communications, Health, Clinical trials, Publishing, Pharmaceutical, Biotechnology, Lung cancer, Cancer, Non-small-cell lung carcinoma, Protein kinase inhibitors, Clinical medicine, Medicine, Health, Tyrosine kinase receptors, Cancer immunotherapy, RBN-2397, Ribon Therapeutics, RBN-2397, RIBON THERAPEUTICS

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397, a small molecule inhibitor of PARP7.

Key Points: 
  • Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first publication in the peer-reviewed journal, Cancer Cell, of preclinical data from its lead asset, RBN-2397, a small molecule inhibitor of PARP7.
  • PARP7 is overexpressed in a number of tumors, including squamous cell carcinoma of the lung (SCCL), which represents approximately 30% of all non-small cell lung cancers.
  • PARP7 is the first monoPARP to be targeted therapeutically and RBN-2397 is the first potent and selective PARP7 inhibitor to enter clinical development.
  • Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease.

Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)

Retrieved on: 
Tuesday, July 20, 2021
Health, Science, Pharmaceutical, Research, Oncology, Lung cancer, Clinical medicine, Medicine, Cancer immunotherapy, Cancer, Non-small-cell lung carcinoma, PD-L1, Breakthrough therapy, PD-1 and PD-L1 inhibitors, Pembrolizumab

Agilent Technologies Inc. (NYSE: A) today announced that the companys PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that the companys PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union.
  • PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) 50% for treatment with Libtayo (cemiplimab).
  • This further demonstrates Agilents commitment to partnering with leading pharmaceutical companies to develop IHC-based diagnostics for targeted cancer therapy.
  • 4th LuCE report on lung cancer: Early diagnosis and screening challenges in lung cancer.